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Early and adequate antibiotic therapy increases the like-
lihood of survival in intensive care unit (ICU) patients
with sepsis [1]. Beta-lactams (BL) are the most fre-
quently prescribed antibiotics because of their broad
spectrum and low toxicity [2]. Supra-therapeutic serum
levels have been suggested to be associated with clinical
toxicity, mainly neurological. In the clinical settings,
determining the optimal dosage is not obvious because
it should take into account the distribution volume and
renal elimination, both being highly variable among
septic patients [3]. Consequently, serum levels of BL are
unpredictable during acute renal failure (ARF) and renal
replacement therapy (RRT).
To describe the prevalence of supra-therapeutic BL
serum levels in septic ICU patients requiring RRT and
their link with toxicity we conducted an observational
retrospective cohort study. We included consecutive pa-
tients who had been sampled for a BL trough serum
level assessment within 7 days of sepsis and 3 days after
intermittent dialysis. Sera were sampled before the next
administration in case of intermittent infusion, and at
24 h in case of continuous infusion. Table 1 shows the
thresholds used and the distribution of the observed
trough levels for each BL.
We included 108 patients, who developed 180 epi-
sodes of sepsis and were sampled 460 times. Their me-
dian Simplified Acute Physiology Score (SAPS) II was 53
(39–66) points. Seventy-four percent of the patients re-
quired vasopressors, and the overall mortality rate in the
ICU was 58 %. Piperacillin (25 %), tazobactam (20 %),
and cloxacillin (18 %) were the most assayed antibiotics.
The distribution of the serum levels was scattered
(Table 1). A supra-therapeutic serum level for at least
one BL was observed in 96/108 (89 %) patients and 156/
180 (86 %) septic events. A level in the highest quartile
was observed for at least one BL in 54/108 (50 %) patients
and 80/180 (45 %) septic events. Supra-therapeutic serum
levels of piperacillin, tazobactam, and cloxacillin were ob-
served in 66, 55, and 31, and were in the highest quartile
in 33, 23, and 14 septic events, respectively. Using a
univariate logistic marginal regression model to ac-
count for the correlation of successive infections in
the same patient, we did not observe a statistical link
between serum overdose and convulsions (n = 8; odds
ratio 1.68 (0.15–18.9); p = 0.67) and mortality (n = 40;
odds ratio 1.28 (0.38–4.33); p = 0.69).
Supra-therapeutic serum levels of BL antibiotics are
commonly observed in our ICU patients with ARF and
RRT. We could not find an association between supra-
therapeutic levels and clinical toxicity.
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Piperacillin 20 77 (44–109)
Tazobactam 5 13 (6–20)
Cloxacillin 20 60 (35–103)
Amoxicillin 20 31 (19–42)
Imipenem 3 3 (1.1–4.2)
Clavulanate 0.5 2 (1.3–3.6)
Ceftazidim 20 71 (49–87)
Cefepime 10 27 (16–47)
a Five times bacterial modal minimal inhibitory concentration [4, 5]
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